Death following COVID-19 vaccination: A case report

Cover Page

Cite item

Abstract

Vaccines are necessary to reduce the mortality and morbidity of infectious diseases. It has played a vital role in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Different types of vaccines have been developed to combat the pandemic. Adverse events following immunization including anaphylaxis have been reported for all types of COVID-19 vaccine. Anaphylaxis is common in a person who has a history of allergic reactions. Adverse reactions develop within minutes or a few hours after vaccination. Thus, in India, vaccine recipients are made to stay in the medical facility for 30 min for observation.

Herein, we report the case of a 23-year-old woman who succumbed after 24 hours of taking COVISHIELD ChAdOx1 nCoV-19 Corona Virus Vaccine (recombinant). She did not have any symptoms after vaccination during her observation at the medical facility and did not have a history of allergic reactions. She was brought dead to M.S. Ramaiah Hospital, and the autopsy revealed pulmonary edema. Antibodies to COVID-19, inflammatory markers, serum IgE, and coagulation indicators in the postmortem blood sample were high. The cause of death was attributed to a delayed allergic reaction to COVISHIELD vaccine. Newer vaccines can cause fatal allergic reaction, sometimes later than expected, even when cutaneous reactions may not be present.

About the authors

Jayanth S. Hosahally

Dr Chandramma Dayananda Sagar Institute of Medical Education & Research

Email: veejay02@gmail.com
ORCID iD: 0000-0001-5209-1133

MD, Associate Professor

India, Devarakaggalahalli

Varsha Patil

Bangalore Medical College Bangalore

Email: dr.varshapatil93@gmail.com
ORCID iD: 0000-0002-5352-6810
India, Bangalore

Girish Y.P. Chandra

MS Ramaiah Medical College

Author for correspondence.
Email: girishchandra14@gmail.com
ORCID iD: 0000-0002-5446-8114

MD, Professor

India, Bangalore

References

  1. Johns Hopkins University & Medicine [Internet]. Coronavirus Resource Center. World Countries India [03.05.2022]. Available from: https://coronavirus.jhu.edu/region/india. Accessed: 15.11.2023.
  2. Alhumaid S, Al Mutair A, Al Alawi Z, et al. Anaphylactic and nonanaphylactic reactions to SARS-CoV-2 vaccines: A systematic review and meta-analysis. Allergy Asthma Clin Immunol. 2021;17(1):109. doi: 10.1186/s13223-021-00613-7
  3. BD-GOV.COM [05.03.2022]. Available from: https://bd-gov.com/cowin-gov-in-vaccination-certificate/. Accessed: 15.11.2023.
  4. The Times of India [Internet]. 2k serious cases of AEFI, 0.004% of 123 crore of shots given [05.03.2022]. Available from: https://timesofindia.indiatimes.com/india/2k-serious-cases-of-aefi-0-004-of-123-crore-of-shots-given-government/articleshow/88153594.cms. Accessed: 15.11.2023.
  5. CNN-News18 [Internet]. 26k Adverse Events, 488 Deaths Reported in India During Covid Vaccination Drive [05.03.2022]. Available from: https://www.news18.com/news/india/26k-adverse-events-488-deaths-reported-in-india-during-covid-vaccination-drive-data-3845363.html. Accessed: 15.11.2023.
  6. Kelso JM. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines. Vaccine. 2021;39(6):865–867. doi: 10.1016/j.vaccine.2020.12.084
  7. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine: United States, December 14–23, 2020. Morb Mortal Wkly Rep. 2021;70(2):46–51. doi: 10.15585/mmwr.mm7002e1
  8. CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 Vaccine: United States, December 21, 2020–January 10, 2021. Morb Mortal Wkly Rep. 2021;70(4):125–129. doi: 10.15585/mmwr.mm7004e1
  9. Somiya M, Mine S, Yasukawa K, Ikeda S. Sex differences in the incidence of anaphylaxis to LNP-mRNA COVID-19 vaccines. Vaccine. 2021;39(25):3313–3314. doi: 10.1016/j.vaccine.2021.04.066
  10. BioProcess International [Internet]. Maggio E. Polysorbates, biotherapeutics and anaphylaxis: A review [September 19, 2017]. Available from: https://bioprocessintl.com/manufacturing/formulation/polysorbates-biotherapeutics-and-anaphylaxis-a-review/. Accessed: 15.11.2023.
  11. Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95(6):593–599. doi: 10.1016/S1081-1206(10)61024-1
  12. Zhao W, Zha X, Wang N, et al. Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: A retrospective cohort study. medRxiv. 2020. doi: 10.1101/2020.03.13.20035436
  13. Pumphrey RS, Roberts IS. Postmortem findings after fatal anaphylactic reactions. J Clin Pathol. 2000;53(4):273–276. doi: 10.1136/jcp.53.4.273

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. Conjunctival congestion.

Download (156KB)
3. Fig. 2. Cyanosis of nail beds.

Download (168KB)
4. Fig. 3. Froth over both nostrils.

Download (218KB)
5. Fig. 4. Intra muscular injection mark present over the outer aspect of left arm.

Download (137KB)
6. Fig. 5. Froth and mucus in trachea.

Download (274KB)
7. Fig. 6. Pulmonary oedema.

Download (241KB)

Copyright (c) 2023 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies